메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한내과학회 대한내과학회지 대한내과학회지 제77권 제1호
발행연도
2009.1
수록면
18 - 25 (8page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Approximately 18,000 cases of colorectal cancer (CRC), accounting for 12.3% of all cancer types, were diagnosed in Korea during 2005. Approximately 20% of these patients were found to have metastatic CRC (mCRC), which has a 5-year survival rate of 10%, at the initial diagnosis. Oxaliplatin- and irinotecan-based combination chemotherapy with infusional 5-FU and leucovorin are currently the standard first-line therapies for mCRC. Recent studies have suggested, however, that survival outcomes can be further improved by adding biologic agents such as cetuximab and bevacizumab to the chemotherapy regimen. Novel treatment strategies involving the increasing number of therapeutic agents are being investigated to improve the efficacy, safety, and tolerability of multi-agent therapy. These strategies have included switching the therapy before progression, maintenance therapy, and chemotherapy-free intervals. Studies have found that the effectiveness of targeted therapies can be linked to the presence or absence of specific genomic changes. Consequently, identifying patients who are amenable to targeted therapy will be essential in daily practice as well as in clinical trials. In the present work, we review recent innovations in chemotherapy for mCRC with a focus on emerging data that may significantly improve both the survival and quality of life for patients with CRC.

목차

등록된 정보가 없습니다.

참고문헌 (20)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0